The findings on orforglipron come from ATTAIN-MAINTAIN, a first-of-its-kind phase 3 trial conducted by the GLP-1 drugmaker Eli Lilly, which manufactures Zepbound and is developing the new oral medication
FMT requires comprehensive donor screening (including MDROs), validated processing with chain-of-custody and retention samples, release criteria, and pharmacovigilance
The mechanism of action includes stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and promoting satiety through central nervous system effects
Su lnea incluye una variedad de opciones diseadas para mejorar la salud y apariencia de la piel
Improving action of antioxidant as Vitamin C, Vitamin E, Coenzyme Q, Glutathione